Nasal Drug Delivery Technology Global Market Report 2023 – By Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels And Ointments, Nasal Powders, Other Dosage Forms), By Container Type (Pressurized Containers, Non-Pressurized Containers), By Therapeutic Application (Allergic And Non-Allergic Rhinitis, Nasal Congestion, Asthma, Vaccination, Other Therapeutic Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Home Care Settings, Hospitals) – Market Size, Trends, And Global Forecast 2023-2032

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drug delivery devices is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the drug delivery devices market report. The regions covered in the drug delivery devices industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The global drugs for immunotherapy market size grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drugs for immunotherapy is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The drugs for immunotherapy market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth. Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of drugs for immunotherapy market are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. North America was the largest region in the immunotherapy market in 2022. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition that describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low-level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones, and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, and testosterone replacement therapy. The various routes of administration are oral, parental, and others which are distributed in hospital pharmacies, retail pharmacies, and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, and others. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications 4) By Route of Administration: Oral, Parental, Other Route of Administration The global drugs for hormonal replacement therapy market size will grow from $12.01 billion in 2022 to $12.66 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for hormonal replacement therapy is expected to grow to $14.63 billion in 2027 at a CAGR of 3.7%. The increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market . Hormonal replacement therapy drugs such as estrogen, progesterone, and others are used to treat medical conditions caused by menopausal conditions. For instance, in February 2021, according to the United Nations Economic and Social Commission for Asia and the Pacific, a Thailand-based regional commission, over half of the people who are over 65 are women, making up over 9% of the total population. By 2050, this percentage is projected to nearly double to more than 18%. From 1.7% to 4.9% of the population, the proportion of people over 80 will almost treble, with women making up over 60% of this group. There are a number of factors that could make older women more vulnerable than older men, including: According to the European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed the male population by 2060, out of which 59.6% of the female population is expected to suffer from postmenopausal symptoms. Thus, the growing female population suffering from menopausal symptoms and the aging population drive the growth of drugs for hormonal replacement therapy market Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co., Hisamitsu Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan PLC., QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech, and TherapeuticsMD. Increasing the occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder the growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. A high dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer, and others. According to an online study, a decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinder the growth of drugs for hormonal replacement therapy. Companies in the drugs for hormonal replacement therapy industry are increasingly developing of drugs for hormonal replacement therapy market with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, virginal estrogen, and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others that occur due to low estrogen levels. Varginalestrogen in the form of cream, vaginal ring, and vaginal tablets is used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low-dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brand’s offerings of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-EstradiolDerm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System, and others. Department Of Health and Human Services of the Food and Drug Administration (FDA), a federal agency, is a regulatory body that monitors, controls, and regulates the drugs for hormone replacement therapy market. For instance, the FDA's Department Of Health and Human Services has revised the requirements for specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by the FDA is to establish the effectiveness and ensure safety for any over-the-counter drug use of these ingredients. North America was the largest region in the drugs for hormonal replacement therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for hormonal replacement therapy market share during the forecast period. The regions covered in the global drugs for hormonal replacement therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The drugs for hormonal replacement therapy market includes revenues earned by entities by treating common menopausal symptoms, including hot flashes and vaginal discomfort. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The drugs for hormonal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides drugs for hormonal replacement therapy market statistics, including drugs for hormonal replacement therapy industry global market size, regional shares, competitors with drugs for hormonal replacement therapy market share, detailed drugs for hormonal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for hormonal replacement therapy industry. This drugs for hormonal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as "blockers" or "adrenoreceptor antagonists," are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types 2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for benign prostatic hypertrophy is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%. The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc. Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA). Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy. Benign prostatic hypertrophy drug manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate the safety and efficacy of drugs using clinical trial data, which will be assessed by competent authorities before authorizing for sale. North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for benign prostatic hypertrophy market share. The regions covered in the global drugs for benign prostatic hypertrophy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction (ED) drugs refer to the drugs that are used to improve the effects of nitric oxide, a substance your body naturally generates that relaxes penile muscles, to treat erectile dysfunction. Erectile dysfunction is the inability to achieve or keep up a penile erection in men. The different types of drugs in erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, and vardenafil. Sildenafil is a drug that is used to treat erectile dysfunction and pulmonary arterial hypertension. It is offered under the trade names Viagra and others. It’s unknown whether it’s effective in treating female genital dysfunction. The different routes of administration include Oral, topical, and injections and are used by hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for erectile dysfunction market is segmented - 1) By Drugs: Sildenafil Citrate, Mirodenafil, Vardenafil 2) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Mode of Administration: Oral, Topical, Injections The global drugs for erectile dysfunction market size will grow from $3.21 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 1.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for erectile dysfunction market size is expected to grow to $3.36 billion in 2027 at a CAGR of 0.8%. The drastic increase in the number of chronic diseases drives the erectile dysfunction drug market. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular diseases, diabetes, obesity, and high blood pressure. According to WHO, the prevalence of chronic diseases is expected to grow by 57% by the end of the year 2020. Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drug market. Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, S.K. Chemicals Co and Teva Pharmaceutical Industries Ltd. Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the patients suffering from erectile dysfunction rejecting or avoiding the treatment. For example, according to a survey conducted by Opinium Research in February 2020, just 27% out of the total 2,006 men surveyed were aware that erectile dysfunction could be linked to high blood pressure or elevated cholesterol while just 22% of men surveyed were aware that erectile dysfunction is often associated with diabetes. These factors restrain the growth of the erectile dysfunction drug market. New drug delivery techniques such as the use of pellets and creams are being implemented by many companies in the erectile dysfunction drugs market. Pellets and creams will have more efficacy and performance in erectile dysfunction and these are also more effective and safer to use. These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, In September 2022, Lupin, an India-based pharmaceutical company launched Sildenafil for oral suspension, 10 mg/mL with the approval of the United States Food and Drug Administration (FDA). This drug is for erectile dysfunction with unique dosages. Medicines are authorized by regulatory bodies based on quality, safety, and efficacy to make sure that medicines are of standard quality and gives positive benefit. Companies are mandated to submit the documentation for the standard quality before applying for authorization. The safety and efficacy of medicines should be demonstrated by clinical trials for all new medicines by the companies. Competent authorities will assess this data before authorizing the drugs. In Europe, the European Medicines Agency (EMA) assesses the drugs for centrally authorized products. North America was the largest region in the erectile dysfunction (ED) drugs market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the global erectile dysfunction (ED) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the erectile dysfunction (ED) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The erectile dysfunction (ED) drugs market research report is one of a series of new reports from The Business Research Company that provides erectile dysfunction (ED) drugs market statistics, including erectile dysfunction (ED) drugs industry global market size, regional shares, competitors with erectile dysfunction (ED) drugs market share, detailed erectile dysfunction (ED) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction (ED) drugs industry. This erectile dysfunction (ED) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Delivery drones are unmanned aerial vehicles (UAVs) capable of carrying lightweight packages. Delivery drones are functioned independently or remotely, with controllers theoretically monitoring several drones at once. The main types of delivery drones are fixed wing drones, rotor drones, and hybrid drones. A fixed wing drone is a rigid structure that has a fixed position rather than moving up and down. The rotor drone is arranged with a tail rotor to control its heading. It is further divided into two types single rotor drone and multi rotor drone, and hybrid drones are a mix of both. These are used for delivery in e-commerce, quick-service restaurants (QSR), and healthcare sectors. The global delivery drones market is segmented - 1) By Drone Type: Fixed Wing Drones, Rotor Drones, Hybrid Drones 2) By Payload: Less than 2 kg, 2–5 kg, More than 5 kg 3) By Application: E-commerce, Quick-service Restaurants (QSR), Healthcare, Others The global delivery drones market size grew from $1.45 billion in 2022 to $1.68 billion in 2023 at a compound annual growth rate (CAGR) of 16.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The delivery drones market size is expected to grow to $4.35 billion in 2027 at a CAGR of 26.8%. The increase in demand for drone deliveries during COVID-19 contributed to the growth of the delivery drones market. During COVID-19, contactless distribution expanded, and drones play a crucial role in ensuring the companies and clients contact as little as needed. Drones were heading to the sky in massive numbers during the pandemic to bring vital goods and drugs to the population in lockdown. In 2020, Alphabet's drone delivery company Wing has seen significant growth in demand as individuals comply with social distancing guidelines during the COVID-19 outbreak. Many individuals have been using the service in recent months as the COVID-19 pandemic continues, and Wing found that between February 2020 and April 2020, in Australia, the use of its service increased by 500%. Therefore, the increasing demand for drone deliveries during COVID-19 drives the growth of the delivery drones market. Major players in the delivery drone market are Airbus SE, DJI Technology Co. Ltd., Flirtey, EHANG, Zipline, Uber Technologies Inc., United Parcel Service of America Inc., Alibaba Group Holding Ltd., Deutsche Post AG, Skycart, FedEx Corporation, Amazon, Wing Aviation LLC, Skycatch, Inc., JD.com, Matternet Inc., and The Boeing Company. The high cost of drone deliveries is expected to impede the growth of the delivery drones market over the coming years. Delivery drones or unmanned aerial vehicles are unmanned aircraft delivering items to a specified location. These are costly because of all the modern technologies that are required to enable them to fly longer, safer and avoid hurdles. For example, the amount United Parcel Service (UPS) charges to customers is $12.92, but the real average price of shipping one product along a path they are already delivering is around $2. Therefore, the high cost of drone deliveries hampers the growth of the delivery drones market. Growing technological advancements are shaping the delivery drones market. Over the past few years, drones have become extremely prevalent as many individuals and organizations are completely accepting and incorporating this technology into their business models. For instance, in May 2022, Skyway, a US-based navigation service provider to urban air mobility (UAM) partnered with Zing Drone Delivery, a US-based drone delivery solutions firm to introduce first-ever food delivery by an advanced drone in Montverde, Florida, the USA. Skyway also started low-altitude weather services with its navigation services to enable safe delivery. This drone delivery offered time savings, efficiency, and convenience for users. In December 2021, Delhivery, an Indian logistics and supply chain company acquired Transition Robotics Inc for an undisclosed amount. The acquisition is part of Delhivery’s efforts towards starting drone delivery in India. Transition Robotics Inc is an American developer of drone or unmanned aerial system (UAS) platforms. North America was the largest region in the delivery drones market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the delivery drone market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the delivery drones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The delivery drones market consists of sales of drones with various types of rotors as well as fixed-wing hybrid drones for small delivery operations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The delivery drones market research report is one of a series of new reports from The Business Research Company that provides delivery drones market statistics, including delivery drones industry global market size, regional shares, competitors with a delivery drones market share, detailed delivery drones market segments, market trends and opportunities, and any further data you may need to thrive in the delivery drones industry. This delivery drones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery is the process of identifying biologically active compounds that possess the potential to become therapeutic agents. The drug discovery process involves different phases, from ideation to development to approval. It is used to discover a new clinical drug for treating new, existing, and previously incurable diseases. The main types of drugs in the drug discovery market are small molecule and large molecule. The small molecules are used to identify small molecules with suitable properties for development. Small molecule refers to a low molecular weight drug that can smoothly penetrate cells. The various processes in drug discovery includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The various technologies in drug discovery includes high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and other technologies. The drug discovery is applied in many therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory disease, and other therapeutic areas. The drug discovery is used by pharmaceutical companies, CROs, and other end-users. The global drug discovery market is segmented - 1) By Drug Type: Small Molecule, Large Molecule 2) By Process: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation 3) By Technology: High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies 4) By Therapeutic Area: Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas 5) By End User: Pharmaceutical Companies, CROs, Other End-Users The global drug discovery market size will grow from $85.42 billion in 2022 to $98.48 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the drug discovery is expected to grow to $158.67 billion in 2027 at a CAGR of 12.7%. Rising healthcare expenditure is expected to propel the drug discovery market going forward. Countries around the world are spending a major share of their GDP on healthcare expenses which include hospital care, physician and clinical services, other professional services, dental services, other health, residential, and personal care, home health care, nursing care facilities, and continuing care retirement communities, prescription drugs, and others. Drug discovery holds a significant part of the health expenditure, as it is required to treat diseases and prolong life. There is an increasing need for new drugs to treat new diseases. For instance, In 2020, the US National Healthcare Expenditure (NHE) grew by 9.7% to $4.1 trillion, accounting for 19.7% of the U.S. Gross Domestic Product (GDP). Therefore, rising healthcare expenditure is expected to propel the drug discovery market growth. Major players in the drug discovery market are Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Agilent Technologies Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories Inc., AstraZeneca PLC, Shimadzu Corp., Evotec SE, Boehringer Ingelheim, Inc., Novartis, Johnson & Johnson, and WIL Research Laboratories. Technological advancements are a key trend in the drug discovery market. Companies operating in the drug discovery market are coming up with various new technologies, such as AI, imaging technology, and others, to reduce the time required for drug discovery. The imaging technology enables non-invasive biological activities occurring within organisms in response to medications to be visualised, characterised, and quantified. These methods, which make use of the strengths of either probes or tissue itself, are crucial for understanding diseases and finding new treatments. For instance, in October 2020, the CU Skaggs School of Pharmacy and Pharmaceutical Sciences, part of Colorado Anschutz, a US-based medical university, announced a new drug discovery technology that includes a new robotic screening and imaging technology which cuts the screening time for new drug therapies by half and also enables rapid and cost-effective screening of hundreds of thousands of potential therapies for diseases. In October 2021, Inotiv, a US-based contract research organization that focuses on nonclinical and analytical drug discovery and development services, acquired Plato BioPharma for $15 million. Through this acquisition, Inotiv intends to execute its strategy of developing a comprehensive range of contract research services spanning the entire drug discovery and preclinical development process. Plato BioPharma is a US-based company specialising in vivo pharmacology research and drug discovery in the cardiovascular, renal, pulmonary, and hepatic therapeutic areas. North America was the largest region in the drug discovery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug discovery market research report is one of a series of new reports from The Business Research Company that provides drug discovery market statistics, including drug discovery industry global market size, regional shares, competitors with a drug discovery market share, detailed drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. This drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug screening is an approach used for drug testing, identified and optimized for clinical trials used in the analysis of blood, urine, hair, or saliva to detect the presence of chemicals and pollutants and other illicit substance left in the body as a result of drug usage. The main types of drug screening products include rapid testing devices, consumables, and others. Rapid testing devices refer to easy-to-use drug screening devices that provide results quicker than the standard traditional laboratory test. The different samples used in drug screening includes oral fluid sample, hair sample, urine sample, breath sample, and others. They are used in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools & colleges. The global drug screening market is segmented - 1) By Products: Rapid Testing Devices, Consumables, Other Products 2) By Sample Type: Oral Fluid Sample, Hair Sample, Urine Sample, Breath Sample, Other Sample Types 3) By End User: Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges The global drug screening market size grew from $6.62 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drug screening is expected to grow to $12.29 billion in 2027 at a CAGR of 13.1%. Growing drug and alcohol consumption is driving the growth of the drug screening market. Drug addiction is a disease that affects a person's brain and behavior, resulting in the inability to control the use of a legal or illegal drug or medication. Substances such as alcohol, marijuana, and nicotine also are considered drugs. As the drug and alcohol addiction increases, the chances of disease are higher which triggers the need for drug screening. For instance, in June 2019 & 2020, according to a report published by the United Nations Office on Drugs and Crime (UNODC), 35 million people globally suffer from drug use disorders and require treatment services. The severity and complexity of the world drug situation are increasing, revealing that the number of people who use drugs is now 30% higher than in 2009. The pandemic effects also ramp up drug risks, as cannabis intake by youth had increased by as much as four times in parts of the world. Therefore, growing drug and alcohol consumption is driving the growth of the drug screening market. Major players in the drug screening market are LabCorp, Quest Diagnostics, Alere, OraSure, Alfa Scientific Designs, Thermo Fisher Scientific, Drägerwerk, LifeLoc, Omega Laboratories, Premier Biotech, Intoximeters, Sciteck Inc., Synens SAS, AccuSource Inc., and Creative Diagnostics. The development of innovative products is a key trend gaining popularity in the drug screening market. Major companies operating in the drug screening market are focusing on providing innovative products to meet fast-growing industry demand and strengthen their market position. Additionally, due to COVID, there was a sudden change in the drug screening approach, which changed the screening methodologies and pushed the innovation and new product development by companies. Companies are striving to develop new products such as a new drug test that is more effective and can be widely used by laboratories. For instance,in November 2020, Axion BioSystems, a US-based life science company, launched the Maestro ZHT high-throughput screening technology, utilizing their knowledge of live-cell equipment to give drug discovery and development a unique perspective. The Maestro ZHT tackles the challenges of finding and evaluating new candidates, capturing complex biology with a straightforward assay, and minimizing cost, time, and the waste of priceless antibodies and cells with a simple, automated, real-time, live-cell assay. In January 2020, StemBioSys, Inc., a Texas-based company involved in the development, manufacturing and distribution of life science tools acquired a majority stake in CarTox, Inc. for an undisclosed amount. This acquisition is expected to boost the company’s product portfolio in the drug screening and drug toxicology sector and contribute to its strategy to expand its business presence across the globe. CarTox, Inc. is a Michigan-based developer and manufacturer of drug screening and drug toxicology solutions. North America was the largest region in the drug screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in the drug screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug screening market research report is one of a series of new reports from The Business Research Company that provides drug screening market statistics, including drug screening industry global market size, regional shares, competitors with a drug screening market share, detailed drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the drug screening industry. This drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.